JP2003515569A - ワクチンアジュバントとして有用なインターロイキン−１ムテイン - Google Patents

ワクチンアジュバントとして有用なインターロイキン−１ムテイン

Info

Publication number
JP2003515569A
JP2003515569A JP2001541535A JP2001541535A JP2003515569A JP 2003515569 A JP2003515569 A JP 2003515569A JP 2001541535 A JP2001541535 A JP 2001541535A JP 2001541535 A JP2001541535 A JP 2001541535A JP 2003515569 A JP2003515569 A JP 2003515569A
Authority
JP
Japan
Prior art keywords
composition
antigen
adjuvant
antigens
mutein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001541535A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003515569A5 (enExample
Inventor
エス ドンダーロ、リチャード
エフ シュターツ、ハーマン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duke University
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duke University filed Critical Duke University
Publication of JP2003515569A publication Critical patent/JP2003515569A/ja
Publication of JP2003515569A5 publication Critical patent/JP2003515569A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2001541535A 1999-12-03 2000-12-04 ワクチンアジュバントとして有用なインターロイキン−１ムテイン Pending JP2003515569A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16892899P 1999-12-03 1999-12-03
US60/168,928 1999-12-03
PCT/US2000/032813 WO2001039803A2 (en) 1999-12-03 2000-12-04 Interleukin-1 muteins useful as vaccine adjuvants

Publications (2)

Publication Number Publication Date
JP2003515569A true JP2003515569A (ja) 2003-05-07
JP2003515569A5 JP2003515569A5 (enExample) 2008-01-31

Family

ID=22613541

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001541535A Pending JP2003515569A (ja) 1999-12-03 2000-12-04 ワクチンアジュバントとして有用なインターロイキン−１ムテイン

Country Status (7)

Country Link
US (2) US6656462B2 (enExample)
EP (1) EP1196193B1 (enExample)
JP (1) JP2003515569A (enExample)
AT (1) ATE413191T1 (enExample)
AU (1) AU1813701A (enExample)
DE (1) DE60040740D1 (enExample)
WO (1) WO2001039803A2 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6270758B1 (en) * 1998-10-08 2001-08-07 Duke University Substantially non-toxic biologically active mucosal adjuvants in vertebrate subjects
BRPI0616446A2 (pt) 2005-09-28 2011-06-21 Cytos Biotechnology Ag composição contendo conjugados de interleucina-1, vacina, uso da vacina, composição farmacêutica, processo para a produção da composição ou da vacina, bem como medicamento
AU2007281934B2 (en) 2006-01-18 2012-11-15 University Of Chicago Compositions and methods related to Staphylococcal bacterium proteins
CA2664418A1 (en) * 2006-09-28 2008-04-03 Cytos Biotechnology Ag Interleukin-1 muteins linked to virus-like particles to treat il-1 associated diseases
US9138470B2 (en) * 2007-11-02 2015-09-22 The Johns Hopkins University Multi-component L2 vaccine for prevention of human papilloma virus infection
US20110262477A1 (en) 2008-10-06 2011-10-27 University Of Chicago Compositions and Methods Related to Bacterial EAP, EMP, and/or ADSA Proteins
HRP20160274T1 (hr) 2009-04-03 2016-04-08 University Of Chicago Pripravci i metode vezane za varijante proteina a (spa)
US8389474B1 (en) * 2009-07-14 2013-03-05 Alan Anson Wanderer Rationale for IL-1 β targeted therapy to improve harvested organ viability, allograft tolerance, replant success and for conditions characterized by reduced or absent arterial perfusion
WO2011100508A2 (en) 2010-02-12 2011-08-18 Arizona Board Of Regents For And On Behalf Of Arizona State University Methods and compositions related to glycoprotein-immunoglobulin fusions
EP2555794A4 (en) 2010-04-05 2014-01-15 Univ Chicago COMPOSITIONS AND METHODS RELATING TO PROTEIN A (SPA) ANTIBODIES AS IMMUNE REACTION AMPLIFIERS
AU2011274367B2 (en) 2010-07-02 2015-04-23 The University Of Chicago Compositions and methods related to protein A (SpA) variants
JP5793194B2 (ja) 2010-09-09 2015-10-14 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ 感染防御ブドウ球菌抗原が関与する方法および組成物
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
WO2013162746A1 (en) 2012-04-26 2013-10-31 University Of Chicago Staphylococcal coagulase antigens and methods of their use
WO2014085767A1 (en) * 2012-11-29 2014-06-05 University Of Rochester Compositions and methods for treating immune conditions, including type1 diabetes
CN104740615A (zh) * 2013-12-31 2015-07-01 上海索菲里奥生物医药科技发展有限公司 IL-1β在制备用于治疗由金黄色葡萄球菌易感所引起的炎症的药物中的用途
TWI601742B (zh) * 2016-03-23 2017-10-11 國立清華大學 使宿主提早產生抗體及延長抗體保護時間的重組雞介白素１β蛋白質及其應用
US10662226B2 (en) 2016-10-28 2020-05-26 The Regents of the University of Caiifomia Synthetic beta-amyloid peptides capable of forming stable antigenic oligomers
WO2019183500A1 (en) 2018-03-23 2019-09-26 Hung Chiung Yu Coccidioides antigens and methods of their use
CA3139981A1 (en) 2019-05-14 2020-11-19 The University Of Chicago Methods and compositions comprising staphylococcus protein a (spa) variants
CA3185087A1 (en) * 2020-07-07 2022-01-13 Nikolai Kley Immunostimulatory adjuvants
US20250177514A1 (en) 2022-01-28 2025-06-05 Pfizer Inc. Coronavirus antigen variants
WO2025027492A1 (en) 2023-07-31 2025-02-06 Pfizer Inc. Coronavirus antigen variants

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63152398A (ja) * 1986-03-14 1988-06-24 Otsuka Pharmaceut Co Ltd インターロイキン−１β誘導体及び医薬
JPH0824595B2 (ja) * 1989-02-27 1996-03-13 ニューイングランド メディカルセンター ホスピタルズ インコーポレイテッド Ｉｌ―１生物活性の抑制剤

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342614A (en) 1984-12-21 1994-08-30 Otsuka Pharmaceutical Co., Ltd. Method of treating arthritus or inflammation with IL-1β or derivatives thereof
US5503841A (en) 1985-09-20 1996-04-02 Cetus Oncology Corporation Human IL-2 as a vaccine adjuvant
IT1217314B (it) 1987-02-20 1990-03-22 Sclavo Spa Nonapeptide sintetico ad attivita'adiuvante capace di potenziare in vivo la risposta anticorporale
DK0482076T3 (da) 1989-07-14 1995-07-17 American Cyanamid Co Stabile vaccinepræparater indeholdende interleukiner
AU651949B2 (en) 1989-07-14 1994-08-11 American Cyanamid Company Cytokine and hormone carriers for conjugate vaccines

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63152398A (ja) * 1986-03-14 1988-06-24 Otsuka Pharmaceut Co Ltd インターロイキン−１β誘導体及び医薬
JPH0824595B2 (ja) * 1989-02-27 1996-03-13 ニューイングランド メディカルセンター ホスピタルズ インコーポレイテッド Ｉｌ―１生物活性の抑制剤

Also Published As

Publication number Publication date
US20040253208A1 (en) 2004-12-16
AU1813701A (en) 2001-06-12
WO2001039803A3 (en) 2002-02-21
US20010036452A1 (en) 2001-11-01
WO2001039803A2 (en) 2001-06-07
US6656462B2 (en) 2003-12-02
DE60040740D1 (de) 2008-12-18
EP1196193A2 (en) 2002-04-17
ATE413191T1 (de) 2008-11-15
EP1196193B1 (en) 2008-11-05

Similar Documents

Publication Publication Date Title
US6656462B2 (en) Interleukin-1 muteins useful as vaccine adjuvants
US5747024A (en) Vaccine adjuvant comprising interleukin-15
AU779388B2 (en) Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US8147819B2 (en) Peptides for active anti-cytokine immunization
JPH10513362A (ja) 生体活性な融合タンパク質および先在する腫瘍の治療
AU2002233560B2 (en) Vaccine
US5100664A (en) Human IL-2 as a vaccine adjuvant
JP2001503014A (ja) 防御免疫応答を増強するための方法
AU2002233560A1 (en) Vaccine
US7452982B2 (en) Immunogenic complex
JPH11502533A (ja) インターロイキン−１０を用いる、特定の抗原に対する抗体応答を増強するための方法
HRP20010824A2 (en) Method for down-regulating il5 activity
NZ533587A (en) Immunogenic mimetics of multimer proteins with promiscuous T cell epitope inserts
JP2002526420A (ja) 脊椎動物における実質的に無毒で生物学的に活性な粘膜アジュバント
AU2005220156B2 (en) Peptides of IL1 beta and TNF alpha and method of treatment using same
WO1992011030A1 (en) Use of il-4 to enhance immune response to immunogens in vaccines
US20050287159A1 (en) Treatment methods for eotaxin mediated inflammatory conditons
AU1208499A (en) Encapsulated immunomodulators useful as vaccine adjuvants
AU2003200723B2 (en) Encapsulated immunomodulators useful as vaccine adjuvants
MXPA05010222A (es) Metodos y composiciones para tratar y prevenir condiciones inflamatorias.
AU2011213784A1 (en) Peptides of IL1 BETA and TNF and method of treatment using same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071204

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071204

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101207

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110719